Compare ANET & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | MRK |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1B | 268.7B |
| IPO Year | 2014 | 1994 |
| Metric | ANET | MRK |
|---|---|---|
| Price | $138.92 | $116.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $173.80 | $123.21 |
| AVG Volume (30 Days) | 7.7M | ★ 10.1M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | ★ 23.32 | 8.01 |
| EPS | 2.75 | ★ 7.28 |
| Revenue | $9,005,700,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $28.79 | $3.74 |
| Revenue Next Year | $21.10 | $5.47 |
| P/E Ratio | $49.14 | ★ $16.58 |
| Revenue Growth | ★ 28.60 | 1.31 |
| 52 Week Low | $59.43 | $75.40 |
| 52 Week High | $164.94 | $125.14 |
| Indicator | ANET | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 45.37 |
| Support Level | $138.18 | $105.23 |
| Resistance Level | $139.93 | $125.14 |
| Average True Range (ATR) | 5.66 | 2.77 |
| MACD | -0.09 | -0.99 |
| Stochastic Oscillator | 64.43 | 14.36 |
Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).